Researchers have found that a genetic change that increases the risk of inflammation, through a process described as ‘explosive’ cell death, is carried by up to 3% of the global population.
The WEHI-led study may explain why some people have an increased chance of developing conditions like inflammatory bowel disease or suffer more severe reactions to infections with bacteria like Salmonella.
At a glance
- MLKL is a gene essential to triggering necroptotic cell death – a natural process that protects our body from infection. In some people this process can go awry and trigger severe tissue damage.
- Study finds a genetic variation, known to enhance the ability of MLKL to kill cells, is carried by up to 3% of the global population.
- The findings could lead to better personalised treatments for inflammation and other diseases in the future.
Immune power of ‘explosive’ cell death
Every minute, millions of cells in our bodies die on purpose. Cell death is an essential process that protects our bodies from disease by removing unwanted, damaged or dangerous cells, and preventing the spread of viruses, bacteria, and even cancer.
WEHI’s Dr Sarah Garnish is first author on the paper and said that while there are various types of cell death, necroptosis is distinguished by its ferocity – the cells essentially explode, which sounds an alarm for other cells in the body to respond.
“This is a good thing in the case of a viral infection, where necroptosis not only kills the infected cells but instructs the immune system to respond, clean things up, and start a more specific, long lived immune response,” Dr Garnish said.
“But when necroptosis is uncontrolled or excessive, the inflammatory response can actually trigger disease.”
Genetic brakes
The gatekeeper of necroptosis is the gene MLKL. When the body needs to trigger a cell death response with plenty of firepower, the cellular brakes that normally keep MLKL in-check are released. However, some of us make a form of MLKL with flimsy brakes.
Dr Garnish and her co-authors have been able to quantify this at a population level for the first time.
“For most of us, MLKL will stop when the body tells it to stop, but 2–3% of people have a form of MLKL that is less responsive to stop signals,” Dr Garnish said.
“While 2-3% doesn’t seem like much, when you consider the global population, this adds up to many millions of people carrying a copy of this gene variant.”
Project leader Dr Joanne Hildebrand said the research proposes that a common genetic change like this can combine with a person’s lifestyle, infection history and broader genetic makeup to increase the risk of inflammatory diseases and severe reactions to infections.
This is known as polygenic risk – the combined influence of multiple genes on developing a certain trait or condition.
“Taking Type 2 diabetes as an example, it’s rare that just one gene change determines whether someone will develop the condition,” Dr Hildebrand said.
“Instead many different genes play a role, as do environmental factors, like diet and smoking.”
Dr Hildebrand said it’s not as simple as directly connecting this difference in the MLKL gene with the chance of someone developing a specific condition.
“We haven’t tagged this MLKL gene variant to any one particular disease yet, but we see real potential for it to combine with other gene variants, and other environmental cues, to influence the intensity of our inflammatory response.”
Towards personalised medicine
Our understanding of MLKL has come a long way since it surfaced by chance in a WEHI lab more than 20 years ago. Today’s research opens the door for future tests and screening to determine disease risks.
Genome sequencing is becoming cheaper and more readily accessible. As more genomic data becomes available to researchers, it increases the likelihood that they can link common genetic variants, like the one described for MLKL, with disease.
In the future researchers hope to pinpoint the genetic changes that might mean someone is more likely to have a severe case of COVID-19, or less likely to bounce back after chemotherapy.
“Every piece of information like this helps us make personalised medicine more of a reality,” said Dr Garnish.
The WEHI team is also investigating whether uncontrolled necroptosis could be beneficial in some circumstances. For example, could people with the MLKL gene variant have a stronger cellular defensive response to certain viruses?
“Gene changes like this don’t usually accumulate in the population over time unless there is a reason for it – they generally get passed on because they do something good,” said Dr Garnish.
“We’re looking at the downsides of having this gene change, but we’re looking for the upsides as well.”
The study “A common human MLKL polymorphism confers resistance to negative regulation by phosphorylation” is now published in Nature Communications (DOI: 10.1038/s41467-023-41724-6).
The research was supported by the National Health and Medical Research Council, the Victorian State Government, the Australian Government Research Training Program Stipend Scholarship and the Wendy Dowsett Scholarship.
WEHI authors: Sarah Garnish, Katherine Martin, Maria Kauppi, Victoria Jackson, Shene Chiou, Yanxiang Meng, Daniel Frank, Emma Tovey, Komal Patel, Annette Jacobsen, Georgia Atkin-Smith, Ladina Di Rago, Marcel Doerflinger, Christopher Horne, Cathrine Hall, Samuel Young, Ian Wicks, Ashley Ng, Charlotte Slade, Andre Samson, John Silke, James Murphy and Joanne Hildebrand.
Image Captions
WEHI researchers
L-R: Project leader Dr Joanne Hildebrand and first author Dr Sarah Garnish.
Credit: WEHI
Necroptosis
Cells dying by necroptosis, an inflammatory form of cell death which is driven by the protein MLKL.
Credit: WEHI
About us:
About WEHI (Walter and Eliza Hall Institute of Medical Research)
WEHI is where the world’s brightest minds collaborate and innovate to make life-changing scientific discoveries that help people live healthier for longer. Our medical researchers have been serving the community for more than 100 years, making transformative discoveries in cancers, infectious and immune diseases, developmental disorders, and healthy ageing. WEHI brings together diverse and creative people with different experience and expertise to solve some of the world’s most complex health problems. With partners across science, health, government, industry, and philanthropy, we are committed to long-term discovery, collaboration, and translation. At WEHI, we are brighter together.
